Equities Analysts Issue Forecasts for BCAX FY2025 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Research analysts at HC Wainwright lowered their FY2025 earnings per share (EPS) estimates for Bicara Therapeutics in a research report issued to clients and investors on Tuesday, November 11th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($2.54) per share for the year, down from their prior forecast of ($2.27). HC Wainwright currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share. HC Wainwright also issued estimates for Bicara Therapeutics’ Q4 2025 earnings at ($0.69) EPS, Q1 2026 earnings at ($0.72) EPS, Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.80) EPS and FY2026 earnings at ($3.03) EPS.

Several other brokerages have also issued reports on BCAX. Weiss Ratings reissued a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Tuesday, October 14th. Wedbush reissued an “outperform” rating and set a $30.00 target price on shares of Bicara Therapeutics in a report on Monday. Wells Fargo & Company raised their price objective on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a report on Tuesday. Finally, Piper Sandler started coverage on Bicara Therapeutics in a research report on Monday, August 18th. They set an “overweight” rating and a $36.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.67.

Bicara Therapeutics Price Performance

Shares of BCAX traded down $0.44 during trading hours on Thursday, hitting $14.47. 57,103 shares of the company were exchanged, compared to its average volume of 598,536. The company has a market capitalization of $792.67 million, a PE ratio of -6.46 and a beta of -0.76. Bicara Therapeutics has a one year low of $7.80 and a one year high of $24.09. The firm has a fifty day simple moving average of $14.81 and a 200-day simple moving average of $12.55.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Monday, November 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.12).

Insider Activity at Bicara Therapeutics

In related news, COO Ryan Cohlhepp sold 39,600 shares of the firm’s stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $18.06, for a total value of $715,176.00. Following the transaction, the chief operating officer owned 205,541 shares in the company, valued at approximately $3,712,070.46. This trade represents a 16.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Claire Mazumdar sold 13,289 shares of Bicara Therapeutics stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $18.84, for a total value of $250,364.76. Following the completion of the transaction, the chief executive officer owned 309,892 shares of the company’s stock, valued at $5,838,365.28. This trade represents a 4.11% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 146,534 shares of company stock worth $2,682,012. 15.50% of the stock is owned by insiders.

Institutional Trading of Bicara Therapeutics

Hedge funds have recently modified their holdings of the company. XTX Topco Ltd raised its stake in shares of Bicara Therapeutics by 4.1% during the 1st quarter. XTX Topco Ltd now owns 28,453 shares of the company’s stock worth $371,000 after purchasing an additional 1,119 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Bicara Therapeutics by 64.1% during the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after buying an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after buying an additional 1,474 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Bicara Therapeutics by 4.8% in the first quarter. Bank of New York Mellon Corp now owns 42,192 shares of the company’s stock worth $550,000 after acquiring an additional 1,924 shares during the period. Finally, Invesco Ltd. raised its position in shares of Bicara Therapeutics by 13.2% in the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company’s stock worth $157,000 after acquiring an additional 1,962 shares in the last quarter.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.